share_log

SenesTech | DEF 14A: Definitive information statements

SenesTech | DEF 14A: Definitive information statements

SenesTech | DEF 14A：股東委託書決議
美股SEC公告 ·  05/29 04:11
牛牛AI助理已提取核心訊息
SenesTech, Inc., a biotechnology company based in Delaware, announced plans for a reverse stock split of its common stock. The reverse stock split, subject to stockholder approval, will be at a ratio not less than 1-for-2 and not more than 1-for-20, as determined by the board of directors. The primary objectives are to increase the per-share market price to comply with Nasdaq's minimum bid price requirement and to enhance capital raising efforts. The company received a notice from Nasdaq regarding non-compliance with the minimum bid price rule and has until August 19, 2024, to regain compliance. The board believes the reverse stock split is the best option to meet Nasdaq's criteria and make the stock more attractive to...Show More
SenesTech, Inc., a biotechnology company based in Delaware, announced plans for a reverse stock split of its common stock. The reverse stock split, subject to stockholder approval, will be at a ratio not less than 1-for-2 and not more than 1-for-20, as determined by the board of directors. The primary objectives are to increase the per-share market price to comply with Nasdaq's minimum bid price requirement and to enhance capital raising efforts. The company received a notice from Nasdaq regarding non-compliance with the minimum bid price rule and has until August 19, 2024, to regain compliance. The board believes the reverse stock split is the best option to meet Nasdaq's criteria and make the stock more attractive to a broader range of investors. The exact timing and ratio of the split will be decided by the board, who may choose not to proceed if market conditions improve. The reverse stock split is not intended as a 'going private transaction' and does not aim to modify stockholder rights materially. If approved, the reverse stock split will reduce the number of outstanding shares, proportionally increase the stock price, and potentially improve liquidity and marketability. The company's board will have the discretion to implement the reverse stock split within one year of stockholder approval at the Annual Meeting.
總部位於特拉華州的生物技術公司SenesTech, Inc. 宣佈了反向拆分普通股的計劃。根據董事會的決定，反向股票拆分的比例將不低於1比2，不超過1比20，但須經股東批准。主要目標是提高每股市場價格，以符合納斯達克的最低出價要求，並加強籌資工作。該公司收到了納斯達克關於不遵守最低出價規則的通知，必須在2024年8月19日之前恢復合規。董事會認爲，反向股票拆分是滿足納斯達克標準並使該股對更廣泛的投資者更具吸引力的最佳選擇。拆分的確切時間和比例將由董事會決定，如果市場狀況改善，董事會可能會選擇不進行拆分。反向股票拆分的目的不是 “私有化交易”，也不是爲了實質性地修改股東權利。如果獲得批准，反向股票拆分將減少已發行股票的數量，按比例提高股價，並有可能提高流動性和適銷性。公司董事會將有權在年會股東批准後的一年內酌情實施反向股票分割。
總部位於特拉華州的生物技術公司SenesTech, Inc. 宣佈了反向拆分普通股的計劃。根據董事會的決定，反向股票拆分的比例將不低於1比2，不超過1比20，但須經股東批准。主要目標是提高每股市場價格，以符合納斯達克的最低出價要求，並加強籌資工作。該公司收到了納斯達克關於不遵守最低出價規則的通知，必須在2024年8月19日之前恢復合規。董事會認爲，反向股票拆分是滿足納斯達克標準並使該股對更廣泛的投資者更具吸引力的最佳選擇。拆分的確切時間和比例將由董事會決定，如果市場狀況改善，董事會可能會選擇不進行拆分。反向股票拆分的目的不是 “私有化交易”，也不是爲了實質性地修改股東權利。如果獲得批准，反向股票拆分將減少已發行股票的數量，按比例提高股價，並有可能提高流動性和適銷性。公司董事會將有權在年會股東批准後的一年內酌情實施反向股票分割。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。